Antibody Discovery Service
A wide range of antibody discovery technologies and techniques have emerged in the past decade, driving a new era of potent antibody therapeutics and therapeutic strategies, including multi-specific antibodies and antibody-drug conjugates. Alfa Cytology has implemented a diverse toolbox of antibody discovery technology platforms to generate highly specific high-affinity antibodies for bladder cancer.
Introduction to Antibody Discovery
The process of antibody discovery involves the utilization of structural computation and library generation to screen the properties of antibodies and antibody-like molecules for subsequent research approaches. The initial phase of discovery primarily focuses on identifying antibody binding properties or "hits" before progressing to pre-clinical. Throughout this discovery phase, antibody researchers customize affinity and stability to achieve improved outcomes for potential therapeutic candidates.
Fig.1 Types of antibody phage display libraries, library construction, and antibody selection. (Zhang Y., 2023)
Our Services
With Alfa Cytology's extensive expertise in antibody discovery, we offer dedicated services for both end-to-end antibody discovery and standalone antibody discovery. Our goal is to be your sole partner for all your antibody discovery needs and beyond.
Immunization Strategies
- Peptide Immunization - Short peptides derived from the target protein are used to immunize animals, typically mice or rabbits.
- Protein Immunization - Full-length or domain-specific proteins are used to immunize animals, leading to the production of antibodies that recognize conformational epitopes on the target protein.
- DNA Immunization - Plasmid DNA encoding the target protein is injected into animals, inducing an immune response that results in the generation of antibodies.
Antibody Library Construction
- Hybridoma Technology - B-cells from immunized animals are fused with myeloma cells to create hybridomas that can be screened for the production of monoclonal antibodies.
- Phage Display - We construct phage display libraries where antibody fragments (such as scFvs or Fab fragments) are displayed on the surface of bacteriophages.
- Single B-cell Sorting - Using flow cytometry, individual B-cells from immunized animals are sorted based on their antigen-binding properties.
Antibody Screening and Selection
- High-throughput Screening - We employ high-throughput screening methods to evaluate thousands of antibody candidates for their binding specificity and affinity to bladder cancer targets. This includes ELISA, surface plasmon resonance (SPR), and flow cytometry-based assays.
- Functional Screening - Selected antibodies are further screened for their functional activities, such as their ability to inhibit cancer cell proliferation, induce apoptosis, or engage immune effector functions.
Contact Us
Collaborate with Alfa Cytology throughout the entire antibody discovery process or selectively utilize their services to effectively develop and evaluate your bladder cancer-specific antibody. To learn more about our services or to discuss your specific research needs, please contact us.
Reference
- Zhang Y. Evolution of phage display libraries for therapeutic antibody discovery. mAbs, 2023, 15(1), 2213793.
For research use only. Not intended for any clinical use.
Related Services
